

## DAFTAR PUSTAKA

- [1] Soelistijo S. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2021. Glob Initiat Asthma. 2021;46.
- [2] IDF. *International Diabetes Federation Diabetes Atlas*. 10th ed; 2021.
- [3] Kementerian Kesehatan RI. Riskesdas 2018. Lap Nas Riskesndas 2018. 2018;44(8):181–222.
- [4] Rivki M, Bachtiar AM, Informatika T, Teknik F, Indonesia UK. Pedoman Pelayanan Kefarmasian pada Pasien Diabetes Melitus. Jakarta: Direktorat Jendral Kefarmasian dan Alat Kesehatan; 2019.
- [5] Dal Canto E, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. *Eur J Prev Cardiol*. 2019;26(2):25–32.
- [6] Kenny HC AE. Heart Failure in Type 2 Diabetes Mellitus: Impact of Glucose-Lowering Agents, Heart Failure Therapies, and Novel Therapeutic Strategies. *Physiol Behav*. 2017;176(1):139–48.
- [7] Kasznicki J, Drzewoski J. Heart failure in the diabetic population-pathophysiology, diagnosis and management. *Arch Med Sci*. 2014;10(3):546–56.
- [8] ADA. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes 2024. *Diabetes Care*. 2024;47(1):179–218.
- [9] Xiang B, Zhao X, Zhou X. Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients. *Cardiovasc Diabetol*. 2021;20(1):1–14.
- [10] Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2019;380(4):347–57.
- [11] Stein, Paul D., Fowler, Sarah E. G. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2019;381(21):1995–2008.
- [12] Lestari, Zulkarnain, Sijid, Aisyah S. *Diabetes Melitus: Review Etiologi, Patofisiologi, Gejala, Penyebab, Cara Pemeriksaan, Cara Pengobatan dan Cara Pencegahan*. UIN Alauddin Makassar. 2021;1(2):237–41.
- [13] Dewi R. *Asuhan Keperawatan pada Pasien dengan Diabetes Mellitus*. Yogyakarta: Deepublish; 2022.
- [14] Salins O. *Medical Surgical Nursing Specialities*. Medical Surgical Nursing Specialities; 2003.
- [15] Health P. Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers. *Clin Diabetes*. 2022;40(1):10–38.
- [16] Akil AAS, Yassin E, Al-Maraghi A, Aliyev E, Al-Malki K, Fakhro KA. Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. *J Transl Med*. 2021;19(1):1–19.
- [17] Galicia-garcia U, Benito-vicente A, Jebari S, Larrea-sebal A. *Costus ignus: Insulin plant and it's preparations as remedial approach for diabetes mellitus*. *Int J Mol Sci*. 2020;1–34.

- [18] Sue E. Huether KLM. *Understanding Pathophysiology Fifth Edition*. US Amerika: Elsevier Mosby; 2012.
- [19] Shahab, Alwi, KEMD F. *Dasar-Dasar Endokrinologi*. Rayyana komunikasindo; 2020.
- [20] Damayanti S,S.Kep.Ns.M.Kep SKM. *Diabetes Melitus & Penatalaksanaan Keperawatan*. Yogyakarta: Nuha Medika; 2016.
- [21] IDAI UEA dan R. *Buku Ajar Endokrinologi Anak*. 1st ed. Jakarta; 2010.
- [22] Maryunani A. *Diabetes pada Kehamilan*. 2nd ed. Jakarta: CV. Trans Info Media; 2013.
- [23] Blum L, Aniekan Ekpenyong. *Diabetes FIP Practice Transformation Programme on NCDs Diabetes prevention, screening and management A handbook for pharmacists*; 2021.
- [24] Dipiro J, Talbert RL, Yee GC, Matzke GR, Wells BG PL. *Pharmacoterapy A Phatophysilogic Approach. AIAA Guidance, Navigation, and Control Conference*; 2015.
- [25] Kambuyono dan Titin. *Peran Rokok dalam Patomekanisme Penyakit Kardiovaskular : Tinjauan Komprehensif dari Molekuler hingga Sosial*. Malang: UB Press; 2022.
- [26] Sowers JR, Lester MA. *Diabetes and cardiovascular disease*. Vol. 22, *Diabetes Care*. 1999.
- [27] Decroli E. *Diabetes melitus Tipe 2*. Padang: Pusat Penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Andalas; 2019.
- [28] Nurhayati. *Sistem Kardiovaskular Keperawatan Dewasa*. Banda Aceh. Syai Kuala University Press;2021.
- [29] Sudoyo AW, Setiyohadi B, Alwi I, K MS. Scan By Dr.Suvianto H.L 15-05-2009. *Buku Ajar Ilmu Penyakit Dalam*. 2009;1825–9.
- [30] Susan dkk. *American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithme 2023 Update*. *Endocrine Practice*.2023;29(2023):305-340.
- [31] Little J, Falace D dkk. *Dental Management of the Medically Compromised Patient Eight Edition*. United State of America: Mosby elsevier; 2013.
- [32] Pabel S, Hamdani N, Luedde M, Sossalla S. *SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravalled?* *Curr Heart Fail Rep*. 2021;18(5):315–28.
- [33] Besmaya BM, Laksono S. *Mekanisme Penghambat Sodium-Glukosa Transport Protein-2 (SGL2-i) pada Penyakit Kardiovaskular: Sebuah Tinjauan*. *MPI (Media Pharm Indones)*. 2023;5(1):71–85.
- [34] Arania R, Triwahyuni T, Esfandiari F, Rama Nugraha F, Moeloek A. *Hubungan antara Usia, Jenis Kelamin, dan Tingkat Pendidikan dengan Kejadian Diabetes Mellitus di Klinik Mardi Waluyo Lampung Tengah*. *Jurnal Medika Malahayati*. 2021; 5 (3): 146-153.
- [35] Kasmawati H. *The Characteristics of Patients with Diabetes Mellitus Type 2 in All Community Health Center, City of Kendari, Southeast Sulawesi in 2016*. *International Journal of Green Pharmacy*. 2017; 11(4):694-696.
- [36] Susilawati, Rahmawati R. *The Relationship Between Age, Sex And Hypertension With The Incidence Of Type 2 Diabetes Mellitus In Tugu Public Health Center, Cimanggis District, Depok City in 2019 Prodi S1 Kesehatan Masyarakat STIKes Raflesia Depok*. *ARKESMAS*. 2021;6(1).

- [37] Rosita R, Kusumaningtiar DA, Irfandi A, Ayu IM. Hubungan Antara Jenis Kelamin, Umur, dan Aktivitas Fisik dengan Diabetes Melitus Tipe 2 Pada Lansia di Puskesmas Balaraja Kabupaten Tangerang. *Jurnal Kesehatan Masyarakat (Undip)*. 2022 May 30;10(3):364–71.
- [38] Imelda. Faktor-Faktor Yang Mempengaruhi Terjadinya diabetes Melitus di Puskesmas Harapan Raya Tahun 2018. *SCIENTIA JOURNAL*. 2019;8(1).
- [39] Fatimah RN. Diabetes Melitus Tipe 2. *J MAJORITY*. 2015;4(5).
- [40] Almaini, A., & Heriyanto, H. (2019). Pengaruh Kepatuhan Diet, Aktivitas Fisik dan Pengobatan dengan Perubahan Kadar Gula Darah pada Pasien Diabetes Mellitus Suku Rejang. *Jurnal Keperawatan Raflesia*, 1(1), 55–66.
- [41] Augustina AT, Siti IA, dan Husnul N. Status Obesitas Dan Kadar Gula Darah Pada Usia Produktif. *Nutrition Scientific Journal*. 2024; 3(1): 44-51.
- [42] Asiimwe D, Mauti GO, Kiconco R. Prevalence and Risk Factors Associated with Type 2 Diabetes in Elderly Patients Aged 45-80 Years at Kanungu District. *J Diabetes Res*. 2020;2020.
- [43] Allorerung D SSJW. Hubungan antara umur, jenis kelamin, tingkat pendidikan dengan kejadian dm tipe 2 di puskesmas ranotana weru kota manado tahun 2016. *J Kesehatan Masyarakat*. 2016;2(1):1–8.
- [44] Kumai DP, Suprapti D, Borneo S, Medika C, Bun P. Hubungan Pola Makan, Kondisi Psikologis, dan Aktivitas Fisik dengan Diabetes Mellitus Pada Lansia di Puskesmas Kumai. Vol. 2, *Jurnal Borneo Cendekia*. 2018.
- [45] Suastika K, Dwipayana P, Siswadi M, Tuty RA. Age is an Important Risk Factor for Type 2 Diabetes Mellitus and Cardiovascular Diseases. In: *Glucose Tolerance*. InTech; 2012.
- [46] Rosa JT dan Syahrizal. Obesitas Sentral dengan Kejadian Hiperglikemia pada Pegawai Satuan Kerja Perangkat Daerah. *HIGEIA*. 2021; 5(3): 354-364.
- [47] Reski EN, Kurniawan D, dan Rustam M. Gambaran Penyakit Komorbid Pada Lansia Yang Dirawat Dengan Covid-19 di Rs Bhayangkara Pekanbaru. *Jurnal Vokasi Keperawatan (JVK)*. 2022; 5(2): 148-155.
- [48] Sjöström CD, Johansson P, Ptaszynska A, List J, Johnsson E. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. *Diab Vasc Dis Res*. 2015 Sep;12(5):352-8.
- [49] Brunström W & Carlberg, B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. *The BMJ*. 2016; 352: i717.
- [50] Kinguchi S, Wakui H, Ito Y, Kondo Y, et al. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study). *Cardiovasc Diabetol*. 2019 Aug 27;18(1):110.
- [51] Hammoud, S., Boubou, A., & Kaddar, N. Antihypertensive effect of Dapagliflozin in Type II diabetic patients with Hypertension. *Research Journal of Pharmacy and Technology*; 2024.
- [52] Li, J., Cheng, P., Huang, C., Jian, L., Wu, Y., & Lin, C. Antihypertensive treatment improves glycemic control in patients with newly diagnosed type 2 diabetes mellitus: A prospective cohort study. *Frontiers in Endocrinology*.

- 2024; 13.
- [53] Susianti Y, Prawistya AS, Rahardjoputro R. Potensi Interaksi Obat Pada Peresepan Obat Peroral Pasien Dewasa Rawat Inap Diabetes Melitus dengan Komorbiditas Hipertensi Di RSUD Dr. Moewardi Surakarta. JIFS. 2023; 3(2): 120-127.
- [54] Aya F, Ozaki, Dennis T, et al. Prescribing patterns and factors associated with sodium–glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease. CMAJ. 2023; 11: 494 - 503.
- [55] Adhitya Pradana. 2014. Hubungan Antara Indeks Massa Tubuh (IMT) dengan Nilai Lemak Viseral. Jurnal Media Medika Muda. Fakultas Kedokteran, universitas Diponegoro.
- [56] Smith U. Abdominal obesity : a marker of ectopic fat accumulation. Journal of clinical investigation. 2015; 125(5): 1790-1792.
- [57] Reghita FS, Hendrianingtyas M, dan Retnoningrum D. Hubungan Lingkar Pinggang dan Visceral Fat dengan Kadar Ferritin Serum pada Obesitas. Jurnal Kedokteran Diponegoro. 2019; 8(2): 701-712.
- [58] Taylor, R., Lee, C., Kyne-Grzebalski, D., Marshall, S. M., & Davison, J. M. Clinical outcomes of pregnancy in women with type 1 diabetes. Obstetrics & Gynecology. 2002; 99(4): 537-541.
- [59] Agustin K, Anggraini Y. Korelasi Usia Perimenopuase Dengan Kejadian Hipertensi Pada Wanita Masa Klimakterium Di Dukuh Ngringin, Bangsri, Karangpandan. Jurnal Pendidikan Tambusai. 2022; 6(2): 9487-9494.
- [60] Viladelvia JK. Dapagliflozin : Manfaat dan Risiko Pada Diabetes Melitus Tipe 2. Jurnal Biomedika Kesehatan. 2019; 2(2); 81-89.
- [61] Wilding, J., Woo, V., Rohwedder, K., Sugg, J., & Parikh, S. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes. 2014; 16: 124-136.

